mol42
15 Nov 2016
PD-L1 [link] all these developments it may seem that we have adequately targeted this pathway, yet the results show that significantly more anti-tumour activity is possible with smaller therapeutic molecules targeting PD-1/ PD-L1 compared with standard antibody molecules, with broader implications that the same advantages could be present for additional immunotherapeutic pathways outside of PD-1 and PD-L1.i like the, presumably, understatement!mol
mol42
02 Nov 2016
Hardman note 021116 [link]
suki the dog
02 Nov 2016
Fantastic 02 November 2016 Avacta Group plc("Avacta" or "the Group" or "the Company"
Avacta announces CAR-T cell therapy research collaboration with major US cancer centre · CAR-T cell therapy is a major new area of cancer therapy that has attracted $billions of investment in the past few years· Affimer technology will potentially provide significant advantages over antibody fragment technology currently used in CAR-T cell modification· Proof-of-concept study with major US cancer centre has the potential to open up highly valuable licensing and partnering opportunities Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, today announces a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta's Affimer technology in novel CAR-T cell-based immunotherapy. CAR-T immunotherapy is a form of cancer treatment in which the patient's own immune system T cells are modified to give them greater potency with which to attack cancer cells (see Notes). Treatments using these engineered immune cells have generated promising responses in patients with advanced cancers and CAR-T immunotherapy has become an intense area of research, clinical development and investment. The simple structure and biophysical properties of Affimers potentially provide significant advantages over antibody fragment technology currently used in CAR-T cell modification and the collaboration announced today is intended to demonstrate a new class of CAR-T cell therapy that incorporate Affimer molecules. The collaboration will be led by Renier J. Brentjens, MD, PhD, Director of Cellular Oncology at Memorial Sloan Kettering Cancer Center in New York. As part of the collaboration Avacta will develop Affimer molecules that bind different regions of CD19, a surface protein specific to B-cells involved in lymphomas. Dr Brentjens' team will construct CAR-T cells incorporating these Affimer molecules and test their anti-tumour function in vitro and in in vivo animal efficacy models. Under the terms of the agreement the ownership of the results generated directly as part of this collaboration will be shared between Avacta and MSK. Alastair Smith, Avacta Group Chief Executive commented: "CAR-T cell therapy is an emerging and very exciting area of immuno-oncology which holds enormous clinical potential. We are delighted to be working with a world-leading team in the field to demonstrate the benefits that Affimer technology could bring to CAR-T therapy. The generation of positive data in these validated models of disease has the potential to open up highly valuable licensing and partnering opportunities for Avacta in this therapy area which has attracted so much attention in the past couple of years."
mol42
22 Oct 2016
Finncap M Brewer interview 201016 finnCap initiate coverage on Avacta, the preclinical stage biopharmaceutical company. finnCap initiate with a 12-month target price of 200p, implying an EV of c£125m/$150m, which they expect to be reached as the company meets its key identified technical preclinical and commercial milestones. [link]
mol42
18 Oct 2016
Biotechandmoney comment here from Alastair[link]
suki the dog
17 Oct 2016
Re: Hardman note 171016 Thought the rns was very positiv
mol42
17 Oct 2016
Hardman note 171016 good write up - pity though they didn't update their sales forecast - 2018 actually down slightly from previous note!though they do sayForecasts do not include any contributions from licensing or milestone income which are lumpy and unpredictablemol
mol42
13 Oct 2016
Zika recent publication in the lancet[link] the top i believebut at least we responded 121016[link] hopefully not only on website!it will take a while for our technology to generate the revenues we all hope but i am prepared to wait - we didn't get our latest grant (3.8m) without demonstrating, in some detail presumably, the potential of affimersmol
Eaglehurst
12 Oct 2016
Re: WHY THE BIG DROP in share price? Suki, What makes you think that the falling £ is detrimental to AVCT? Surely it makes selling their services/technology overseas cheaper in foreign currency terms and so could act to improve income.E
drunkasaskunk
11 Oct 2016
Re: WHY THE BIG DROP in share price? Well sometimes it's kindest to be frank, and - frankly - I remember being 'invested' when Alistair had been sending out all the signals that the company had no liquidity issues (he might have even stated this explicitly - I can't quite recall as it's admittedly going back a bit now, but this only shows how trust issues linger) only to go ahead with a hugely discounted, seemingly 'mates rate' placing very shortly afterwards. Good luck if you're a holder - seriously, there's much to be excited about here but once bitten...
joseph w
11 Oct 2016
Re: WHY THE BIG DROP in share price? Thank both,suki the dog and drunkasaskunk for your kind contributions.
suki the dog
10 Oct 2016
Re: WHY THE BIG DROP in share price? Maybe because of £ getting slaughter
drunkasaskunk
10 Oct 2016
Re: WHY THE BIG DROP in share price? Could be a simple trust issue, and it would be understandable if so!
joseph w
10 Oct 2016
WHY THE BIG DROP in share price? Can somebody tell me what's going on ?I thought things were on the up.
mol42
01 Oct 2016
agrisera bit of info [link] from above aug 16A few weeks ago, the small Swedish company had been list-ed as one of the “fastest growing companies” in a research anti-body market report. It was placed between large companies on the world antibody market such as EMD Millipore and Thermo Fishe r. That’s a pleasant success for Nordlund, who is now ap-proaching retirement age (he is 67). albeit we don't mention them on our partner page![link] jan 15Commercial Partnership Targeting the Agri-bio Reagents Market [link]
